Impact of DHA intake in a mouse model of synucleinopathy

[1]  A. Schapira,et al.  α-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection , 2017, The Journal of Biological Chemistry.

[2]  M. Bortolanza,et al.  Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase , 2017, Nutritional neuroscience.

[3]  Rob Knight,et al.  Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease , 2016, Cell.

[4]  R. Bazinet,et al.  N-3 polyunsaturated fatty acids in animal models with neuroinflammation: An update. , 2016, European journal of pharmacology.

[5]  F. Cicchetti,et al.  Partial neurorescue effects of DHA following a 6-OHDA lesion of the mouse dopaminergic system. , 2016, The Journal of nutritional biochemistry.

[6]  M. Goedert,et al.  Synucleinopathies: past, present and future , 2016, Neuropathology and applied neurobiology.

[7]  Paul J. Barrett,et al.  Post-translational modification of α-synuclein in Parkinson׳s disease , 2015, Brain Research.

[8]  M. Chesselet,et al.  Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson’s Disease , 2015, Journal of Parkinson's disease.

[9]  G. Petsko,et al.  Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations , 2015, The Lancet Neurology.

[10]  D. Mann,et al.  Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology , 2015, Neurobiology of Disease.

[11]  M. Emanuele,et al.  Mechanisms of Alpha-Synuclein Action on Neurotransmission: Cell-Autonomous and Non-Cell Autonomous Role , 2015, Biomolecules.

[12]  Simon C. Dyall,et al.  Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA , 2015, Front. Aging Neurosci..

[13]  M. Chesselet,et al.  Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons , 2014, Neurobiology of Disease.

[14]  E. Morya,et al.  Omega-3 deficiency and neurodegeneration in the substantia nigra: involvement of increased nitric oxide production and reduced BDNF expression. , 2014, Biochimica et biophysica acta.

[15]  Jose A. Santiago,et al.  The emerging role of nutrition in Parkinson's disease , 2014, Front. Aging Neurosci..

[16]  P. Calder.  n-3 Fatty acids, inflammation and immunity: new mechanisms to explain old actions , 2013, Proceedings of the Nutrition Society.

[17]  E. Bézard,et al.  Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies , 2013, Movement disorders : official journal of the Movement Disorder Society.

[18]  F. Cicchetti,et al.  MyD88 deficiency results in both cognitive and motor impairments in mice , 2012, Brain, Behavior, and Immunity.

[19]  D. Surmeier,et al.  Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease , 2012, Behavioural Brain Research.

[20]  Y. Yaari,et al.  α‐Synuclein Neuropathology is Controlled by Nuclear Hormone Receptors and Enhanced by Docosahexaenoic Acid in A Mouse Model for Parkinson's Disease , 2012, Brain pathology.

[21]  M. Chesselet,et al.  A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice , 2012, Neurotherapeutics.

[22]  C. Song,et al.  Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease , 2012, Behavioural Brain Research.

[23]  Tapan P. Patel,et al.  Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death , 2011, Neuron.

[24]  F. Calon,et al.  Accumulation of Dietary Docosahexaenoic Acid in the Brain Attenuates Acute Immune Response and Development of Postischemic Neuronal Damage , 2011, Stroke.

[25]  F. Cicchetti,et al.  Impact of omega-3 fatty acids in Parkinson's disease , 2011, Ageing Research Reviews.

[26]  D. Selkoe,et al.  α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation , 2011, Nature.

[27]  M. Chesselet,et al.  Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α‐synuclein , 2011, Journal of neuroscience research.

[28]  E. Bézard,et al.  A tale on animal models of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[29]  F. Calon,et al.  DHA Improves Cognition and Prevents Dysfunction of Entorhinal Cortex Neurons in 3xTg-AD Mice , 2011, PloS one.

[30]  F. Cicchetti,et al.  Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease , 2011, Journal of Lipid Research.

[31]  B. Davletov,et al.  Alpha-synuclein, lipids and Parkinson's disease. , 2010, Progress in lipid research.

[32]  W. Schulz-Schaeffer.  The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia , 2010, Acta Neuropathologica.

[33]  J. Anselmo-Franci,et al.  Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease , 2010, Neuroscience Research.

[34]  C. Cepeda,et al.  Alpha‐synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway , 2009, Journal of neuroscience research.

[35]  E. Bézard,et al.  Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms , 2009, The Lancet Neurology.

[36]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[37]  L. Bubacco,et al.  Molecular insights into the interaction between alpha-synuclein and docosahexaenoic acid. , 2009, Journal of molecular biology.

[38]  F. Cicchetti,et al.  Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[39]  S. Dunnett,et al.  Tests to assess motor phenotype in mice: a user's guide , 2009, Nature Reviews Neuroscience.

[40]  F. Cicchetti,et al.  Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α‐synuclein inclusions , 2009, Journal of neurochemistry.

[41]  M. Vohl,et al.  Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE ɛ4 but not by the common PPAR-α L162V polymorphism in men , 2009, British Journal of Nutrition.

[42]  M. Levine,et al.  Alterations in corticostriatal synaptic plasticity in mice overexpressing human α-synuclein , 2009, Neuroscience.

[43]  R. Munhoz,et al.  Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. , 2008, Journal of affective disorders.

[44]  M. Farrer,et al.  Genomic investigation of α‐synuclein multiplication and parkinsonism , 2008, Annals of neurology.

[45]  F. Cicchetti,et al.  Beneficial effects of dietary omega‐3 polyunsaturated fatty acid on toxin‐induced neuronal degeneration in an animal model of Parkinson's disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  F. Cicchetti,et al.  Can we prevent Parkinson’s disease with n-3 polyunsaturated fatty acids? , 2008 .

[47]  D. Selkoe,et al.  Polyunsaturated Fatty Acids Induce α-Synuclein-Related Pathogenic Changes in Neuronal Cells , 2007 .

[48]  J. Kordower,et al.  Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? , 2007, Neurobiology of Disease.

[49]  J. Trojanowski,et al.  Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery , 2006, Neuron.

[50]  S. Chalon.  Omega-3 fatty acids and monoamine neurotransmission. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.

[51]  M. Chesselet,et al.  Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism , 2006, Behavioural pharmacology.

[52]  Zhiming Wen,et al.  Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. J. Koudstaal,et al.  Dietary fatty acids and the risk of Parkinson disease , 2005, Neurology.

[54]  Jonathan Salcedo,et al.  Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α-Synuclein , 2004, The Journal of Neuroscience.

[55]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[56]  A. Singleton,et al.  Association between cardiac denervation and parkinsonism caused by α‐synuclein gene triplication , 2004 .

[57]  Charles N. Serhan,et al.  Altered Fatty Acid Composition of Dopaminergic Neurons Expressing α-Synuclein and Human Brains with α-Synucleinopathies* , 2003, Journal of Biological Chemistry.

[58]  Makoto Hashimoto,et al.  Transgenic Models of α‐Synuclein Pathology , 2003 .

[59]  Matthew P Frosch,et al.  The Formation of Highly Soluble Oligomers of α-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease , 2003, Neuron.

[60]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[61]  P. Blanchet,et al.  Effect of MPTP‐induced denervation on basal ganglia GABAB receptors: Correlation with dopamine concentrations and dopamine transporter , 2001, Synapse.

[62]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[63]  J. Langston,et al.  The native form of α-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls , 1998, Neuroscience Letters.

[64]  R. Drucker-Colín,et al.  A new motor test sensitive to aging and dopaminergic function , 1991, Journal of Neuroscience Methods.

[65]  G. Pascal,et al.  Alterations in the Fatty Acid Composition of Rat Brain Cells (Neurons, Astrocytes, and Oligodendrocytes) and of Subcellular Fractions (Myelin and Synaptosomes) Induced by a Diet Devoid of n‐3 Fatty Acids , 1984, Journal of neurochemistry.

[66]  C. Tanner,et al.  Dietary fat intake, pesticide use, and Parkinson's disease. , 2014, Parkinsonism & related disorders.

[67]  D. Selkoe,et al.  Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. , 2007, The American journal of pathology.

[68]  M. Chesselet,et al.  Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[69]  A. Singleton,et al.  Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. , 2004, Brain : a journal of neurology.

[70]  D. Selkoe,et al.  Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. , 2003, The Journal of biological chemistry.

[71]  G. Spiller,et al.  New protective roles for selected nutrients , 1989 .